ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
Completed
Addex Pharma S.A.
Phase 2
The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in
Parkinson's disease patients following four weeks of dosing.
The secondary objectives of the study include the evaluation of the efficacy of ADX48621
compared with placebo in reducing levodopa induced dyskinesia in patients with Parkinson's;
the evaluation of the effect of ADX48621 on symptoms of Parkinson's disease and patient
ability to function, and the evaluation of the effect of coadministration of ADX48621 on
L-dopa efficacy.
PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
Completed
Addex Pharma S.A.
Phase 1
This is an open label study, non-randomized, positron emission tomography (PET)study
investigating mGlu5 receptor occupancy after single or two oral dosing of ADX48621 in healthy
subjects using [18F]-FPEB as the radiotracer.
PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
Completed
Johns Hopkins University
Phase 1
This is an open label study, non-randomized, positron emission tomography (PET)study
investigating mGlu5 receptor occupancy after single or two oral dosing of ADX48621 in healthy
subjects using [18F]-FPEB as the radiotracer.
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
Addex Pharma S.A.
Phase 2/Phase 3
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients
with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg
per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the
Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment
period may have the option to roll into an open-label safety extension study for an
additional 12-month treatment period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
